<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01110811</url>
  </required_header>
  <id_info>
    <org_study_id>D2009-10</org_study_id>
    <nct_id>NCT01110811</nct_id>
  </id_info>
  <brief_title>Transoral Incisionless Fundoplication (TIF) Versus Sham for Treatment of Gastroesophageal Reflux Disease (GERD)</brief_title>
  <official_title>A Randomized Controlled Trial Comparing Transoral Incisionless Fundoplication (TIF) Using EsophyX With Sham Procedure for the Treatment of PPI Dependent GERD: the TIF vs. Sham Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EndoGastric Solutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EndoGastric Solutions</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to evaluate the relative merits, safety and effectiveness of transoral&#xD;
      incisionless fundoplication (TIF) in proton pump inhibitor (PPI) dependent GERD patients&#xD;
      compared with sham procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Effectiveness Endpoint: The proportion of patients in clinical remission after 6&#xD;
      months (without being classified as treatment failure).&#xD;
&#xD;
      Secondary Effectiveness: PPI consumption, esophageal acid exposure, reduction in QOLRAD and&#xD;
      GSRS scores and healing of reflux esophagitis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients in clinical remission</measure>
    <time_frame>at 6 month follow-up</time_frame>
    <description>Fifty nine per cent of patients remained in clinical remission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in symptoms</measure>
    <time_frame>at 6 moths follow-up</time_frame>
    <description>GSRS score improved from 14 (range 10-21) to 10 (range 6-19) with P = 0.004.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalized esophageal acid exposure</measure>
    <time_frame>at 6 months follow-up</time_frame>
    <description>Sixty nine per cent of patients (69%) in TIF surgical arm normalized esophageal acid exposure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healed reflux esophagitis</measure>
    <time_frame>at 6 months follow-up</time_frame>
    <description>In 80% of patients healing of esophagitis was observed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <condition>Hiatal Hernia</condition>
  <arm_group>
    <arm_group_label>TIF procedure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transoral Incisionless Fundoplication (TIF)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham procedure</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The intervention on the Sham procedure consisted of an upper gastrointestinal endoscopy, or EGD.(esophagogastricduodenoscopy).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transoral Incisionless Fundoplication (TIF)</intervention_name>
    <description>The TIF procedure results in the creation of an esophago-gastric fundoplication extending up to 4 cm above the Z-line and 270 degress around the esophagus.</description>
    <arm_group_label>Sham procedure</arm_group_label>
    <arm_group_label>TIF procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-80 years&#xD;
&#xD;
          -  On daily PPIs for &gt; 6 months&#xD;
&#xD;
          -  Documented PPI dependency&#xD;
&#xD;
          -  Persistent GERD symptoms without PPI therapy during the titration phase of the study&#xD;
&#xD;
          -  Evidence of two or more of the following while off PPI therapy (&gt; 10 days):&#xD;
&#xD;
          -  Erosive esophagitis (Los Angeles grade A-C)&#xD;
&#xD;
          -  Abnormal ambulatory pH study&#xD;
&#xD;
          -  Moderate to severe GERD symptoms&#xD;
&#xD;
          -  Normal or near normal esophageal motility (by manometry)&#xD;
&#xD;
          -  Patient willing to cooperate with post-operative dietary recommendations and&#xD;
             assessment tests&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI &gt; 35&#xD;
&#xD;
          -  Hiatal hernia &gt; 3 cm&#xD;
&#xD;
          -  Esophagitis LA grade D&#xD;
&#xD;
          -  Esophageal ulcer&#xD;
&#xD;
          -  Esophageal stricture&#xD;
&#xD;
          -  Barretts esophagus (Prague: C&gt;1, M&gt;2)&#xD;
&#xD;
          -  Esophageal motility disorder&#xD;
&#xD;
          -  Severe gastric paralysis&#xD;
&#xD;
          -  Pregnancy or plans for pregnancy in the next 12 months&#xD;
&#xD;
          -  Immunosuppression&#xD;
&#xD;
          -  ASA &gt; 2&#xD;
&#xD;
          -  Portal hypertension and/or varices&#xD;
&#xD;
          -  History of previous resective gastric or esophageal surgery, cervical spine fusion,&#xD;
             Zenker's diverticulum, esophageal epiphrenic diverticulum, achalasia, scleroderma or&#xD;
             dermatomyositis, eosinophilic esophagitis, or cirrhosis&#xD;
&#xD;
          -  Active gastro-duodenal ulcer disease&#xD;
&#xD;
          -  Gastric outlet obstruction or stenosis&#xD;
&#xD;
          -  Severe gastroparesis or delayed gastric emptying confirmed by solid-phase gastric&#xD;
             emptying study if patient complains of postprandial satiety during assessment&#xD;
&#xD;
          -  Coagulation disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Lundell, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University, Huddinge Hospital, Stockholm, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nantes Hospital</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University, Ersta Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University, Huddinge Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>April 23, 2010</study_first_submitted>
  <study_first_submitted_qc>April 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2010</study_first_posted>
  <last_update_submitted>March 4, 2019</last_update_submitted>
  <last_update_submitted_qc>March 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GERD</keyword>
  <keyword>Esophagitis</keyword>
  <keyword>Fundoplication</keyword>
  <keyword>Anti-reflux surgery</keyword>
  <keyword>PPI dependent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Esophagitis, Peptic</mesh_term>
    <mesh_term>Hernia, Hiatal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

